Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10127.123 | 0.7705 | 0.4855 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10127.123 | 0.6737 | 0.2747 | 0.8767 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9777.124 | 0.9807 | 0.9387 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9777.124 | 1.1952 | 1.6568 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9777.124 | 0.9879 | 0.9616 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9777.124 | 1.2944 | 2.0167 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9777.124 | 1.1516 | 1.5043 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9777.124 | 1.1347 | 1.4459 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9777.124 | 0.9589 | 0.8706 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9777.124 | 0.9468 | 0.8331 | 0.6278 | |
| SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9777.124 | 1.1661 | 1.5548 | 0.6278 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 10146.124 | 1.0756 | 1.1632 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 10146.124 | 1.0954 | 1.2059 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 10146.124 | 1.2093 | 1.4536 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 10146.124 | 1.0665 | 1.1435 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10146.124 | 1.0606 | 1.1307 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10146.124 | 1.1205 | 1.2604 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10146.124 | 1.0401 | 1.0864 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10146.124 | 1.0766 | 1.1652 | 0.9296 | |
| SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10146.124 | 0.9399 | 0.8709 | 0.9296 | |
| UACC-812 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 10267.026 | 1.1821 | 2.4162 | 0.3125 | |
| UACC-812 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 10267.026 | 1.0575 | 1.3919 | 0.3125 | |
| UACC-812 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 10267.026 | 1.1591 | 2.2081 | 0.3125 | |
| UACC-812 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 10267.026 | 0.8904 | 0.3792 | 0.3125 | |
| UACC-812 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10267.026 | 0.9851 | 0.9062 | 0.3125 |